Erythropoietin treatment for non-uremic patients: a personal view.
The correction of anemia in patients with chronic renal failure (CRF) has become the most important application of recombinant human erythropoietin (rHuEpo). The merits of rHuEpo therapy in patients with CRF are overt. Firstly, patients with CRF have an absolute deficiency in endogenous erythropoietin production and a relatively low maintenance dose of rHuEpo (often less than 100 IU/kg body weight per week) is effective in avoiding regular transfusions in the majority of the patients with CRF. Secondly, rHuEpo is able to avoid long-term complications of frequent transfusions (hemochromatosis, transfusion-transmissible diseases). Thirdly, patients with uremia notice a considerable improvement in quality of life (QOL) after initiation of rHuEpo. These advantages justify administration of this costly drug in CRF patients. The use of rHuEpo outside the setting of uremia do, however, not cover the complete spectrum of beneficial effects as compared to its use in (pre)dialysis patients. The aim of this overview is to provide some annotations on recently approved (cisplatin-induced anemia, preoperative anemia, zidovudine-related anemia) and possibly future (several types of malignancy and inflammation) indications for rHuEpo in non-uremic patients, leaving out the correction of anemia due to relatively uncommon disorders in the Dutch population (such as sickle cell anemia and thalassemia).
Biesma
D H
DH
Department of Internal Medicine, St. Antonius Ziekenhuis, CM Nieuwegein, The Netherlands.
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D019380:Anti-HIV Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000150:complications; D001804:Blood Transfusion, Autologous; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000150:complications; D009190:Myelodysplastic Syndromes / Q000150:complications; D011994:Recombinant Proteins; D014511:Uremia / Q000150:complications; D015215:Zidovudine / Q000009:adverse effects
D019380:Anti-HIV Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D015215:Zidovudine